Company Overview - NLS Pharmaceutics is a global development-stage biopharmaceutical company focused on innovative therapies for rare and complex central nervous system disorders [4] - Kadimastem is a clinical stage cell therapy company developing proprietary cell products for various neurodegenerative conditions [5][6] Merger Details - NLS has successfully closed an initial $500,000 from a $1 million fundraising round at a share price of $3.10, which is a 48% increase above the market price at the time [1] - The merger with Kadimastem aims to create a combined Nasdaq-traded biotechnology company with a strong pipeline of advanced therapies [1][3] - NLS has filed an F-4 Registration Statement with the SEC detailing the proposed merger [2] Leadership Statements - Alex Zwyer, CEO of NLS, expressed excitement about the merger, highlighting its potential to enhance shareholder value and redefine the biotechnology landscape [3] - Ronen Twito, CEO of Kadimastem, emphasized the merger's potential to create a powerful entity in the biotechnology sector and unlock new growth opportunities [3]
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS